Companies
Cornell University Licenses UBR5 Inhibitor Program to Bridge Medicines
The New York-based drugmaker will further develop the anti-UBR5 molecules for treatment-resistant TNBC and ovarian cancers
In Brief This Week: Day One, Sophia Genetics, Genetron Health, Global Cancer Technology
News items for the week of July 26, 2021.
Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent
Revenues from pharmaceutical products were almost entirely driven by the COVID-19 treatment remdesivir, though sales of Kite Pharma's CAR T-cell therapies grew, too.
Blueprint Medicines Q2 Revenues Increase More Than 200 Percent
In the second quarter, Blueprint reported $8.5 million in revenue from Ayvakit and $2.9 million in revenue from Gavreto.
Merck Q2 Revenues Grow 22 Percent
The company's pharmaceutical revenues were led by robust sales of Keytruda, which racked up $4.18 billion during the quarter.
Jul 29, 2021
AstraZeneca Q2 Revenues Increase 31 Percent
Jul 28, 2021
Pfizer Nearly Doubles Q2 Revenues
Jul 28, 2021
Bristol Myers Squibb Q2 Revenues Grow 16 Percent
Jul 28, 2021
Strata Oncology Raises $90M in Series C Financing
Jul 21, 2021